| ［1］ |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209–249.
|
| ［2］ |
Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)[J]. Ann Oncol, 2020, 31(12): 1623–1649.
|
| ［3］ |
Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer[J]. N Engl J Med, 2016, 375(20): 1925–1936.
|
| ［4］ |
Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer[J]. N Engl J Med, 2022, 386(10): 942–950.
|
| ［5］ |
Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer[J]. J Clin Oncol, 2017, 35(32): 3638–3646.
|
| ［6］ |
Sledge GW Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: A randomized clinical trial[J]. JAMA Oncol, 2020, 6(1): 116–124.
|
| ［7］ |
Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer[J]. Nat Genet, 2013, 45(12): 1439–1445.
|
| ［8］ |
Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer[J]. Nat Genet, 2013, 45(12): 1446–1451.
|
| ［9］ |
Jeselsohn R, Buchwalter G, De Angelis C, et al. ESR1 mutations: A mechanism for acquired endocrine resistance in breast cancer[J]. Nat Rev Clin Oncol, 2015, 12(10): 573–583.
|
| ［10］ |
Fanning SW, Mayne CG, Dharmarajan V, et al. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation[J]. eLife, 2016, 5: e12792.
|
| ［11］ |
Chandarlapaty S, Chen D, He W, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: A secondary analysis of the BOLERO-2 clinical trial[J]. JAMA Oncol, 2016, 2(10): 1310–1315.
|
| ［12］ |
Brett JO, Spring LM, Bardia A, et al. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer[J]. Breast Cancer Res, 2021, 23(1): 85.
|
| ［13］ |
Zundelevich A, Dadiani M, Kahana-Edwin S, et al. ESR1 mutations are frequent in newly diagnosed metastatic and locoregional recurrence of endocrine-treated breast cancer and carry worse prognosis[J]. Breast Cancer Res, 2020, 22(1): 16.
|
| ［14］ |
Bidard FC, Hardy-Bessard AC, Dalenc F, et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): A randomised, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2022, 23(11): 1367–1377.
|
| ［15］ |
Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, HER2-negative advanced breast cancer: results from the randomized phase Ⅲ EMERALD trial[J]. J Clin Oncol, 2022, 40(28): 3246–3256.
|
| ［16］ |
Bardia A, Cortes J, Bidard FC, et al. Elacestrant in ER-positive, HER2-negative metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase Ⅲ EMERALD trial[J]. Clin Cancer Res, 2024, 30(19): 4299–4309.
|
| ［17］ |
Burstein HJ, DeMichele A, Somerfield MR, et al. Testing for ESR1 mutations to guide therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: ASCO guideline rapid recommendation update[J]. J Clin Oncol, 2023, 41(18): 3423–3425.
|
| ［18］ |
Andre F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer[J]. N Engl J Med, 2019, 380(20): 1929–1940.
|
| ［19］ |
Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor-positive advanced breast cancer[J]. N Engl J Med, 2023, 388(22): 2058–2070.
|
| ［20］ |
Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and HER2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2023, 402(10411): 1423–1433.
|